Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Melanoma

• Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
• Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
• Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
• Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma
• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
• Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
• A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
• Intratumoral PH-762 for Cutaneous Carcinoma
• A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
• Naltrexone and Propranolol Combined With Immunotherapy
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
• GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
• A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
• Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
• The Safety and Efficacy of Endostar Combined With Toripalimab as Postoperative Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
• A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
• Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
• Perioperative Treatment With Tranexamic Acid in Melanoma
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
• Melphalan Chemoreduction for Ocular Melanoma
• Biomarkers in Immunotherapy of Melanoma
• ACT-TIL and ANV419 for Advanced Melanoma.
• OH2 Injection in Melanoma
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
• Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number.
• A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
• The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
• Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
• Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
• Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
• A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers
• Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
• (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
• Study to Evaluate KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
• IMM60 and Pembrolizumab in Melanoma and NSCLC
• Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
• XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
• Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
• A Phase 1/2 Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors
• Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
• MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
• Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
• A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
• A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
• MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma
• A Study to Evaluate the Superiority of the Fianlimab and Cemiplimab Combination Compared to Pembrolizumab in Adult and Adolescent Patients With Completely Resected High-Risk Skin Cancer
• Intrathecal Double Checkpoint Inhibition
• Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
• A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101).
• A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
• A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
• A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
• Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
• A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
• Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
• Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
• Adjuvant Melatonin for Uveal Melanoma
• Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
• Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
• A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
• Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
• Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
• Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
• A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
• Efficacy and Safety of TQB2618 Injection Combined With Terriprizumab Injection in Patients With Advanced Melanoma
• Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
• FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
• A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma
• A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
• A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
• Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
• Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
• A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
• A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
• Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
• OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
• Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
• Study of EVX-01 Vaccine in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
• Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
• "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
• CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
• Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
• CD8+ PET Companion Trial
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut
• Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• A Phase II Trial of HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
• A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
• Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
• Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
• HL-085 in NRAS-mutated Advanced Melanoma
• A Phase II Clinical Trial Evaluating Ipilimumab, Nivolumab, and Cabozantinib in Patients With Anti-PD-1(L1) Refractory Cutaneous Melanoma
• Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
• Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
• Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
• Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
• A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
• Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
• RAPA-201 Therapy of Solid Tumors
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
• A Study of RC48-ADC in Advanced Melanoma Subjects With HER2-positive
• GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
• Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
• Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
• To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
• Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
• Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
• Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors
• Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma
• A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
• Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis
• A Study to Test How BI 765063 is Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
• Biomarker-driven Therapy for Melanoma
• A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
• Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
• Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
• IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
• Pembrolizumab + Infliximab for Metastatic Melanoma
• A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
• Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM
• Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
• Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
• 68Ga-grazytracer PET/CT in Subjects With Non-small Cell Lung Cancer or Melanoma
• Axitinib + Ipilimumab in Advanced Melanoma
• A Study of SEA-CD40 Given With Other Drugs in Cancers
• Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
• GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
• DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
• Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
• A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
• A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
• Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
• Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
• NeoVax + CDX-301 and Nivolumab in Advanced Melanoma
• Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy
• L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
• A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors
• A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers
• ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
• Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
• Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
• Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION
• Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
• Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery
• FLX475 in Combination With Ipilimumab in Advanced Melanoma
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
• A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
• FHD-286 in Subjects With Metastatic Uveal Melanoma
• The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
• Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
• A Study of PRT1419 in Patients With Advanced Solid Tumors
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.
• A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
• Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
• Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
• A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Part
• Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
• Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
• Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
• A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• A Study of HX008 for the Treatment of Patients With Malignant Melanoma
• Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma
• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
• Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
• Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
• Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
• Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma
• Sargramostim (GM-CSF) + PD-1
• Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
• CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
• CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
• Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
• Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
• Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma
• Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
• Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
• A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• A Study to Assess LBL-007 in Combination With Toripalimab in Subjects With Advanced Melanoma
• Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
• NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma
• Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
• Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
• TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
• Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
• Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
• BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
• Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
• A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
• Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
• Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
• A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
• Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
• Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
• A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors
• Neoadjuvant T-VEC in High Risk Early Melanoma
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
• Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
• Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab
• Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
• OH2 Injection in Solid Tumors
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
• Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
• A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma
• Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
• Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
• Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
• Infliximab for Treatment of Ipilimumab Colitis
• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
• Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
• Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
• Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• PHP and Immunotherapy in Metastasized UM
• The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
• Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
• A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
• Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer
• A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
• Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
• Surgery of Melanoma Metastases After Systemic Therapy
• Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
• Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
• Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
• A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
• Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
• Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
• Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response in Melanoma or NSCLC Participants
• Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
• A Study of ZN-c3 in Participants With Solid Tumors
• A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors
• Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
• Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
• Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
• NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
• A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
• PVSRIPO in Combination With Nivolumab in Melanoma
• Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
• IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
• Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
• Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
• Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
• Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
• A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
• Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
• Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
• CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
• TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
• SBRT as a Vaccination for Metastatic Melanoma
• A Study of SGN-CD228A in Advanced Solid Tumors
• Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma
• Neoadjuvant Atezolizumab in Cutaneous Melanoma
• The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
• Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
• Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases
• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
• ATL001 in Patients With Metastatic or Recurrent Melanoma
• PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
• High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
• Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
• PDR001 + Panobinostat for Melanoma and NSCLC
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
• MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
• A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment
• Study of HL-085 in NRAS Mutant Advanced Melanoma
• Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
• Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
• PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
• Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
• Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma
• MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
• Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
• Nab-PCE vs PC for MM After Failure of Anti-PD-1
• An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
• Tinostamustine and Nivolumab in Advanced Melanoma
• Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
• High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
• A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
• Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
• Radiation and Combination Immunotherapy for Melanoma
• Neoadjuvant Combination Immunotherapy for Stage III Melanoma
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
• Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
• Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
• A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.
• Study of INBRX-105 in Patients With Solid Tumors
• Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
• This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
• Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
• An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
• Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
• Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
• Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
• Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
• Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
• Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
• CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
• Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
• Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
• Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
• Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
• A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma
• MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
• Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
• Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
• Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
• Safety of ADU-1604 in Adults With Metastatic Melanoma
• Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
• TIL and Anti-PD1 in Metastatic Melanoma
• C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central N
• Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
• CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
• Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
• A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
• Pembrolizumab and EDP1503 in Advanced Melanoma
• A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
• NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
• Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
• A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
• Melanoma Metastasized to the Brain and Steroids
• Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
• TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
• Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
• UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
• Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
• Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
• A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
• Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
• Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
• To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
• Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
• Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
• Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
• TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
• MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
• Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
• A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
• Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
• A Phase Ⅲ Study to Investigate Toripalimab Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
• A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• Treating Patients With Melanoma and ALK Alterations With Ensartinib
• A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
• Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
• A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
• Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
• Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma
• Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
• Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
• Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
• Fecal Microbiota Transplant (FMT) in Melanoma Patients
• Dabrafenib and/or Trametinib Rollover Study
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
• Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
• E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
• Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
• Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
• A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
• Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
• A Study of PLX2853 in Advanced Malignancies.
• SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
• REO13 Melanoma With of Without GM-CSF
• 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
• Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
• Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
• Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
• Phase Ib of L-NMMA and Pembrolizumab
• Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
• Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
• Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
• Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untr
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
• Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma
• QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
• Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
• SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
• To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
• Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
• A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma
• Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
• Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
• SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
• CD40 Agonistic Antibody APX005M in Combination With Nivolumab
• A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
• LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
• Dendritic Cell Vaccination in Patients With Advanced Melanoma
• Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
• Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
• Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
• A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
• Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
• A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
• Study in Subjects With Small Primary Choroidal Melanoma
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
• Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
• Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
• Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
• Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
• Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
• ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
• A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
• An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
• Safety and Efficacy of DCB-BO1301 in Advanced Melanoma
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
• Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
• A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
• Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
• A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
• Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
• Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
• MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients
• Treatment of Advanced Solid Tumor With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
• A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
• Ipilimumab and Nivolumab in Leptomeningeal Metastases
• Neoadjuvant L19IL2/L19TNF- Pivotal Study
• Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
• A Clinical Trial of Patients With Melanoma
• Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
• Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
• Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
• Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
• 18F-FLT PET Imaging in Patients With Advanced Melanoma
• IMCgp100-401 Rollover Study
• Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
• BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
• Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
• Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
• A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
• Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
• Yervoy Pregnancy Surveillance Study
• Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
• HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
• A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
• X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
• Duration of Anti-PD-1 Therapy in Metastatic Melanoma
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
• Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
• Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
• A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
• Imaging FDG Flare in Melanoma
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
• Intermittent Selumetinib for Uveal Melanoma
• A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
• Pembrolizumab-PET Imaging
• A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
• Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
• Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
• Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
• Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
• First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
• XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
• Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
• Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
• Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
• APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
• Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
• Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Diseas
• Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
• Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
• A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
• Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
• A Sunscreen Based on Bioadhesive Nanoparticles
• A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
• Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
• Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
• BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
• Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
• Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
• A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma
• A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
• Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
• Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
• Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
• Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
• Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
• A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
• Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
• A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
• A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
• Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
• A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
• Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
• Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
• MRI and PET to Assess Pembrolizumab Response
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
• Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
• GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
• Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
• myDC/pDC in Stage III Melanoma Patients
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
• A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
• Trial of Pembrolizumab and Radiotherapy in Melanoma
• PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
• A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
• Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
• Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
• Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
• A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
• Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
• Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
• A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
• Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
• A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
• Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
• Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
• Cytokine-induced Killer Study for Patients With Stage II Melanoma
• Trial of pIL-12/MK-3475 in Metastatic Melanoma
• In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
• Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
• Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
• Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
• Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma
• Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
• Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
• Safety Study of AMG 228 to Treat Solid Tumors
• Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
• A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
• A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
• Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
• Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
• Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
• Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
• Vemurafenib Plus Cobimetinib in Metastatic Melanoma
• A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
• Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
• Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
• Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
• Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
• A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
• Radiotherapy & Combi in Metastatic Melanoma
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
• A Study of rSIFN-co in Subjects With Advanced Solid Tumors
• A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
• A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
• Peginterferon and TIL Therapy for Metastatic Melanoma
• TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
• Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
• Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy
• Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
• Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
• Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
• Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
• Vemurafenib and TIL Therapy for Metastatic Melanoma
• Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
• Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
• MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
• Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
• Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
• Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)
• Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
• Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
• A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
• Phase IIB TL + YCWP + DC in Melanoma
• Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
• Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
• Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
• Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
• PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
• Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
• Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
• Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
• Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)
• RTA 408 Capsules in Patients With Melanoma - REVEAL
• Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
• Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
• Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
• YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
• A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
• Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
• Adoptive Therapy Using Antigen-Specific CD4 T-Cells
• Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
• Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
• Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
• A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
• Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
• Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
• Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
• Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma
• Fluorescence Surgery for Sentinel Node Identification in Melanoma
• Expanded Access Program With Nivolumab to Treat Melanoma
• Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
• A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
• A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
• Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
• Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
• GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
• Treatment of Advanced Melanoma With MK-3475 and Peginterferon
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
• A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
• Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
• Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
• Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
• Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
• MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
• A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
• Intratumoral Administration of L19IL2/L19TNF
• Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
• PLX3397 KIT in Acral aNd mucOsal Melanoma
• Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
• A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
• A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
• Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
• Biomarker Correlates of Hypoxia in Metastatic Melanoma
• Infrared Lymphangiography as a Method of Sentinel Node Identification
• Immunotherapy Study for Patients With Stage IV Melanoma
• Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
• Ipilimumab 12-month Intensive Pharmacovigilance Protocol
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
• Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
• Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
• RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
• Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
• Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
• Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
• Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
• Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
• A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
• Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
• A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
• TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
• Efficacy of Propranolol Treatment to Prevent Melanoma Progression
• Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients
• A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
• Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
• Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
• Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
• Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
• MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
• Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
• Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
• Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
• Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
• Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
• T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
• Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
• The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
• Trametinib With GSK2141795 in BRAF Wild-type Melanoma
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
• Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
• Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
• Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
• A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
• An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
• Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
• Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
• A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
• BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
• Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
• A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
• Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
• Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
• Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
• Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
• Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
• Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
• A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
• HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
• A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
• Radiation Use During Vemurafenib Treatment
• Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
• Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
• Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
• Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
• Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
• Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
• A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
• The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
• Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
• A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
• Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells
• A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
• A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
• Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
• Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
• A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
• A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
• A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
• Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
• Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
• EF5 in Melanoma Patients
• Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
• Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
• Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
• Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
• Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
• Ipilimumab and Imatinib Mesylate in Advanced Cancer
• Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
• Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
• LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
• Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
• Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
• Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
• Study of Ipilimumab in the Immune System
• Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
• Bevacizumab vs Dacarbazine in Metastatic Melanoma
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
• Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
• Interleukin-2 in Metastatic Melanoma
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
• Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
• Dacarbazine and Carmustine in Metastatic Melanoma
• Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
• Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
• HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
• Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
• A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
• Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel
• Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
• Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
• A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
• A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
• A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Me
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
• A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and P
• Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
• Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
• Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
• Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
• Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
• Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
• A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
• Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
• Doxycycline, Temozolomide and Ipilimumab in Melanoma
• Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
• Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
• Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
• A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
• Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
• Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
• A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied
• A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
• Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
• STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
• A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
• Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
• Metronomic Therapy in Patients With Metastatic Melanoma
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
• Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
• Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
• BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
• RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
• Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
• Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
• A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
• Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
• Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
• DNA Repair Inhibitor & Irradiation on Melanoma
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
• Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
• Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
• Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
• Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
• Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
• Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
• Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
• Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
• IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
• IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
• Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
• A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
• A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
• A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
• Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
• An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
• Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
• Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
• Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
• THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
• NAM-Trial: Multiferon in Malignant Melanoma
• Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
• Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
• Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
• Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
• A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
• A Study of Vemurafenib in Participants With Metastatic Melanoma
• A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
• Nuclear and Near-Infrared (NIR) Imaging in Melanoma
• Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
• Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
• IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
• Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
• Drosophila-generated CTL
• A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
• A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
• High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
• PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
• MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients
• Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
• A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
• Lapatinib in Stage IV Melanoma With ERBB4 Mutations
• Nordic Adjuvant IFN Melanoma Trial
• Docetaxel With or Without AZD6244 in Melanoma
• A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
• Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
• RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
• Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
• A Study of RO5185426 in Patients With Metastatic Melanoma
• Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
• GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
• Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
• A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
• Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
• RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
• Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
• Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
• A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
• Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
• IMCgp100 in Advanced Unresectable Melanoma
• Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
• STA-9090(Ganetespib) in Metastatic Ocular Melanoma
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
• A Study of PNT2258 in Patients With Advanced Solid Tumors
• Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
• Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
• Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
• A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
• Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
• Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
• A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
• A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
• A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
• Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
• A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
• Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
• An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
• Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
• E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
• Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
• High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
• Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
• Ipilimumab + Temozolomide in Metastatic Melanoma
• Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
• A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
• Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
• Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
• Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
• Study of Nilotinib in Metastatic Melanoma With KIT Aberrations
• Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
• Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
• An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
• A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
• A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
• Panobinostat (LBH589) in Patients With Metastatic Melanoma
• Phase II Study of Tesetaxel in Metastatic Melanoma
• Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
• Can We Miss Pigmented Lesions in Psoriasis Patients?
• Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
• Study of Weekly LOC-paclitaxel Injection for Melanoma
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
• Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
• Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
• Rituximab in Metastatic Melanoma
• QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
• A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
• Dinaciclib in Treating Patients With Stage III-IV Melanoma
• Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
• Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
• Dose Escalation Study of MLN4924 in Adults With Melanoma
• A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
• Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
• Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
• Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
• A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
• A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
• Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
• Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
• Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
• A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
• SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
• A Study to Assess PV-10 Chemoablation of Cancer of the Liver
• Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
• Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
• Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
• Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
• Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
• Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
• Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
• Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
• Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
• A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
• Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
• Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
• Dinaciclib in Treating Patients With Stage IV Melanoma
• Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
• Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Pa
• Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
• Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
• Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
• Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
• Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
• Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
• Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
• Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
• Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
• Pilot Study of IFN α2b for Melanoma Patients
• Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
• Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
• MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
• A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
• Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
• Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
• A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
• Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
• Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients
• Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
• Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
• Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
• Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
• Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
• An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
• Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
• Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
• Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
• Treatment Of Radiation Retinopathy Trial
• A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
• Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
• Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
• Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
• Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
• Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
• Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
• Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
• Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
• Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
• Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
• Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
• A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
• Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
• Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
• Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
• A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
• 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
• A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
• Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
• Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
• Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
• Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
• Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
• Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
• Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
• Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
• Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
• Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
• Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
• Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
• Study of Temzolomide and Gleevec in Advanced Melanoma
• Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
• Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
• Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
• A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
• CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
• Clinical Trial of Sutent to Treat Metastatic Melanoma
• In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
• A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
• Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
• Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
• Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
• Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
• Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
• Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
• PTK/ZK in Disseminated Malignant Melanoma
• Phase II, 2nd Line Melanoma - RAND Monotherapy
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
• Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
• Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
• Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
• ABT-510 in Treating Patients With Metastatic Melanoma
• Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
• A Phase I/II Study of Dasatinib and Dacarbazine
• Treatment With Intravitreal Avastin for Large Uveal Melanomas
• RAD001 Plus Bevacizumab in Metastatic Melanoma
• Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
• Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
• Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
• A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
• Treatment Use Study for Advanced Melanoma.
• Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
• SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
• Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
• Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
• Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
• A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
• Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
• Fotemustine in Treating Patients With Metastatic Melanoma
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
• Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
• Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
• Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment
• A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine
• Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
• Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
• Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
• Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
• A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
• Taxotere/Temodar/Cisplatin Study in Melanoma Patients
• Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
• Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
• Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
• Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
• Study of ADI-PEG 20 in Patients With Advanced Melanoma
• Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
• Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
• Vaccination Plus Ontak in Patients With Metastatic Melanoma
• Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
• Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma
• Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
• Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients
• Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
• Biochemotherapy With Temozolomide for Metastatic Melanoma
• Fibrin Melanoma Axillary Node Study in Patients With Melanoma
• Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
• Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
• A Phase I/II Study of Sunitinib and Dacarbazine
• Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
• Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
• A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
• Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
• A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
• Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
• Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
• Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
• Lovastatin in Treating Patients At High Risk of Melanoma
• High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
• Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
• High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma
• Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema
• Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
• A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)
• Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
• A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
• A Study to Assess APO866 for the Treatment of Advanced Melanoma
• Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
• Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
• Imatinib in Adult Patients With Metastatic Ocular Melanoma
• Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
• A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
• Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
• Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
• Abraxane and Temodar Plus Genasense in Advanced Melanoma
• Safety Study of PLX4032 in Patients With Solid Tumors
• Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
• Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
• Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
• Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
• A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
• Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
• A Study of Tasisulam in Treating Participants With Malignant Melanoma
• 131-I-TM-601 Study in Adults With Solid Tumors
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
• Sentinel Node With Ultrasound Contrast in Melanoma
• A Study of Volociximab in Metastatic Melanoma
• Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
• GM-CSF as Adjuvant Therapy of Melanoma
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
• Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
• Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
• Efficacy Study of IL-21 to Treat Metastatic Melanoma
• Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
• Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
• Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
• Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
• Post-Operative Drainage Following Lymph Node Dissection
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
• Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
• Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
• RFT-5-dgA in Patients With Metastatic Melanoma
• Dendritic Cell Vaccination During Lymphoid Reconstruction
• Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
• A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
• Temodar and Sutent as Therapy for Melanoma
• Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
• Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
• Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
• Phase II Trial of Ontak With Metastatic Melanoma
• IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
• Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
• A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
• Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
• Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
• A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
• Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
• Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
• Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
• A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
• TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
• Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
• CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
• Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
• Disulfiram in Patients With Metastatic Melanoma
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• Study of CP-675,206 in Refractory Melanoma
• Melanoma Vaccine With Peptides and Leuprolide
• Taxoprexin Treatment for Advanced Skin Melanoma
• A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
• Taxoprexin® Treatment for Advanced Eye Melanoma
• AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
• PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
• Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
• Clinical Study of Previously Untreated Patients With Malignant Melanoma
• Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
• Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
• PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
• Intralesional PV-10 Chemoablation of Metastatic Melanoma
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
• Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
• Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
• Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
• Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
• Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
• Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
• Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
• A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
• Use of 852A in Metastatic Cutaneous Melanoma.
• Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
• Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
• Study of Metastatic Ocular Melanoma
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
• Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
• NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
• Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
• Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
• A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
• Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
• Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
• A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
• Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
• Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
• Pain Relief - Tramadol Versus Ibuprofen
• A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
• Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
• Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
• Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
• Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
• S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
• FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
• Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
• Everolimus in Treating Patients With Stage IV Melanoma
• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
• SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
• Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
• Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
• Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
• Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
• Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
• Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
• Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
• Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
• Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
• A Pilot Study of Pivanex in Patients With Malignant Melanoma
• Tanespimycin in Treating Patients With Stage III-IV Melanoma
• CP-675,206 In Patients With Advanced Melanoma
• Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
• Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
• Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
• Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma
• STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
• Study of Talabostat and Cisplatin in Advanced Melanoma
• Study of Talabostat in Advanced Melanoma
• Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
• ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
• Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
• Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
• Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
• PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
• Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
• A Phase II Study of UCN-01 in Metastatic Melanoma
• Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
• Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
• CPG 7909 Injection in Melanoma
• Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
• Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
• Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma
• Study of PI-88 in Patients With Advanced Melanoma
• Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
• Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
• CP-461 in the Treatment of Patients With Advanced Melanoma
• Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
• Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
• Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
• Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
• Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
• Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
• Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
• Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
• Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
• BMS-247550 in Treating Patients With Stage IV Melanoma
• EPO906 Therapy in Patients With Advanced Melanoma
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
• Decitabine in Treating Patients With Advanced Solid Tumors
• ADI-PEG in Patients With Metastatic Melanoma
• Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
• Imatinib Mesylate in Treating Patients With Metastatic Melanoma
• Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
• Isotretinoin in Preventing Skin Cancer
• PS-341 in Treating Patients With Metastatic Malignant Melanoma
• CCI-779 in Treating Patients With Metastatic Melanoma
• Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain
• Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
• Vaccine Therapy in Treating Patients With Metastatic Cancer
• Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
• Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
• Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
• Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
• Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma
• E7070 in Treating Patients With Stage IV Melanoma
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
• Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
• Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
• S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
• Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
• Thalidomide and Dacarbazine for Metastatic Melanoma
• Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
• Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma
• Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
• SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
• Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
• Irofulven in Treating Patients With Stage IV Melanoma
• O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
• Nitrocamptothecin in Treating Patients With Metastatic Melanoma
• Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
• Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
• Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
• Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
• Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
• PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
• Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
• S9804: Vinorelbine in Treating Patients With Stage IV Melanoma
• Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
• Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
• Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
• Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
• Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
• Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
• Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
• Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
• Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
• Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
• Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
• Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
• Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma
• Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
• Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
• Biological Therapy in Treating Patients With Metastatic Cancer
• Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
• Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
• Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
• Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
• A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma